The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder.

ABSTRACT:

Objectives

Major depressive disorder (MDD) is a common and serious disorder with significant impact on patients and families. The goal of this retrospective cohort study was to determine the economic burden among patients with MDD stratified by number of treatment lines needed for episode resolution.

Methods

Truven Health Analytics MarketScan^® claims data were used to identify US patients (≥ 18 years) who were diagnosed with MDD and started on an antidepressant between 2013 and 2017. A generalized linear model estimated direct and employment-related costs for the first 12 months following initiation of treatment across cohorts with increasing number of lines of MDD pharmacotherapy. Analyses were adjusted for demographics and clinical factors.

Results

A tota

SUBMITTER: Arnaud A 

PROVIDER: S-EPMC8166719 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature